Education
About Us
Working with TipRanks
Follow Us
PharmaCielo (PCLOF)
OTHER OTC:PCLOF
PCLOF Stock Chart & Stats
$0.01
<$0.01(6.14%)
At close: 4:00 PM EST
$0.01
<$0.01(6.14%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.12
Previous CloseN/A
Volume1.75K
Average Volume (3M)9.90K
Market Cap
$6.75M
Enterprise Value$28.84M
Total Cash (Recent Filing)$256.57K
Total Debt (Recent Filing)$17.82M
Price to Earnings (P/E)―
Beta-1.27
Next Earnings
May 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding187,893,690
10 Day Avg. Volume17,743
30 Day Avg. Volume9,897
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.87
Price to Sales (P/S)4.03
P/FCF Ratio-7.12
Enterprise Value/Market Cap4.27
Enterprise Value/Revenue9.21
Enterprise Value/Gross Profit120.66
Enterprise Value/Ebitda-12.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Medical/pharma FocusA dedicated medical and pharmaceutical-cannabinoid focus positions the company in higher-barrier, regulated end markets. Structural demand for compliant cannabinoid inputs and specialized processing can support durable commercial relationships and pricing stability versus commodity recreational segments.
Return To Positive Gross ProfitRestoring positive gross profit indicates the core cultivation and processing economics can cover direct production costs. If sustained, this improvement provides a foundation to absorb SG&A and move toward operating profitability as volumes and operational efficiency scale.
Reduced Cash BurnA materially smaller operating cash outflow versus prior years extends runway and lowers near-term financing pressure. Continued reduction in cash burn is a durable indicator of improving operational control and increases the chance of reaching self-funded operations absent adverse shocks.
Bears Say
Negative Equity / Weak Balance SheetNegative equity reflects accumulated losses and a fragile capital base. High debt relative to small assets elevates insolvency and refinancing risk, constrains strategic flexibility, and raises the cost or scarcity of additional capital until equity is rebuilt or debt materially reduced.
Persistent Negative Cash FlowSustained negative operating and free cash flow forces ongoing external financing, increasing dilution or leverage. This structural cash shortfall limits capacity to invest in growth, maintain facilities, or weather regulatory and market volatility without securing fresh capital.
Declining Revenue And Deep LossesA meaningful revenue decline combined with extreme negative net margins signals the core business remains unprofitable at scale. Without persistent revenue recovery or significant cost restructuring, operating losses will continue to erode liquidity and shareholder value.
PharmaCielo News
PCLOF FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was <$0.01 and its highest was $0.12 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is $6.75M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is May 04, 2026 which is in 60 days.
How were PharmaCielo’s earnings last quarter?
PharmaCielo released its earnings results on Mar 02, 2026. The company reported $0.001 earnings per share for the quarter, beating the consensus estimate of N/A by $0.001.
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 187,893,690 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
PharmaCielo reported an EPS of $0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in PCLOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., together with its subsidiary, cultivates, processes, produces, and supplies medicinal-grade cannabis extracts, tetrahydrocannabinol, and related products. The company also offers telemedicine software. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies in Canada and Colombia. The company has a strategic alliance with AssuredTrans Inc. PharmaCielo Ltd. is headquartered in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―
Ownership Overview
Options Prices
Currently, No data available
---